A phase 2 trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC).

被引：9
|
作者：
Petrylak, Daniel Peter
Smith, David C.
Appleman, Leonard Joseph
Fleming, Mark T.
Hussain, Arif
Dreicer, Robert
Sartor, A. Oliver
Shore, Neal D.
Vogelzang, Nicholas J.
Youssoufian, Hagop
DiPippo, Vincent A.
Stambler, Nancy
Huang, Kathleen
Israel, Robert Joseph
机构：
[1] Yale Univ, Med Ctr, New Haven, CT USA
[2] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[3] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[4] Virginia Oncol Associates, US Oncol Res, Hampton, VA USA
[5] Univ Maryland, Ctr Canc, Baltimore, MD 21201 USA
[6] Cleveland Clin, Cleveland, OH 44106 USA
[7] Tulane Univ, New Orleans, LA 70118 USA
[8] Atlantic Urol Clin, Carolina Urol Res Ctr, Myrtle Beach, SC USA
[9] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[10] Progen Pharmaceut Inc, Tarrytown, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.5023
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5023
引用
收藏
页数：1
相关论文
共 50 条
  • [31] PROGNOSTIC VALUE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) RECEIVING PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) TARGETED RADIONUCLIDE THERAPY
    Stangl-Kremser, Judith
    Sun, Michael
    Ho, Benedict
    Thomas, Joseph
    Nauseef, Jones
    Osborne, Joseph
    Molina, Ana
    Sternberg, Cora
    Nanus, David
    Bander, Neil
    Tagawa, Scott
    JOURNAL OF UROLOGY, 2023, 209 : E384 - E385
  • [32] A phase Ib trial of enzalutamide with venetoclax in metastatic castration-resistant prostate cancer (mCRPC).
    Gopalakrishnan, Dharmesh
    Kirk, Jason
    Davis, John
    George, Saby
    Levine, Ellis Glenn
    Beumer, Jan Hendrik
    Appleman, Leonard Joseph
    Tang, Dean
    Chatta, Gurkamal S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] MEDI3726, a prostate-specific membrane antigen (PSMA)-targeted antibody-drug conjugate (ADC) in mCRPC after failure of abiraterone or enzalutamide
    De Bono, Johann S.
    Fleming, Mark T.
    Wang, Judy Sing-Zan
    Cathomas, Richard
    Williams, Marna
    Bothos, John G.
    Balic, Kemal
    Cho, Song Hye
    Martinez, Pablo
    Petrylak, Daniel Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [34] Radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 for metastatic castration-resistant prostate cancer (CRPC).
    Akhtar, N. H.
    Nanus, D. M.
    Vallabhajosula, S.
    Osborne, J.
    Beltran, H.
    Tyrell, L.
    Nadeau, K.
    Saran, A.
    Mileo, G.
    Goldsmith, S. J.
    Bander, N. H.
    Tagawa, S. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [35] Long-term adverse events (AE) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving prostate-specific membrane antigen (PSMA)-based targeted radionuclide therapy (TRT).
    Sun, Michael
    Thomas, Charlene
    Ho, Benedict
    Niaz, Muhammad Junaid
    Molina, Ana M.
    Sternberg, Cora N.
    Nanus, David M.
    Bander, Neil Harrison
    Tagawa, Scott T.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] Preclinical evaluation of AMG 160, a next-generation bispecific T cell engager (BiTE) targeting the prostate-specific membrane antigen PSMA for metastatic castration-resistant prostate cancer (mCRPC).
    Bailis, Julie
    Deegen, Petra
    Thomas, Oliver
    Bogner, Pamela
    Wahl, Joachim
    Liao, Mike
    Li, Shyun
    Matthes, Katja
    Naegele, Virginie
    Rau, Doris
    Rattel, Benno
    Raum, Tobias
    Kufer, Peter
    Coxon, Angela
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [37] The Auckland experience with Lutetium-177 prostate-specific membrane antigen (177LU-PSMA-617) in advanced, metastatic castration-resistant prostate cancer (mCRPC): 2018-2020
    Hitchen, Nadia
    Waldron, Nick
    Lawrence, Nicola
    Fu, Simon
    Jacobs, Carmel
    Hanning, Fritha
    Lim, Remy
    Fong, Peter
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 67 - 67
  • [38] Dramatic prostate-specific antigen response with activated hemicellulose compound in metastatic castration-resistant prostate cancer
    Turner, Jeffrey
    Chaudhary, Uzair
    ANTI-CANCER DRUGS, 2009, 20 (03) : 215 - 216
  • [39] Prostate-specific antigen testing in men with metastatic castration-resistant prostate cancer treated with docetaxel chemotherapy
    Tsai, Yuh-Shyan
    Tzai, Tzong-Shin
    UROLOGICAL SCIENCE, 2015, 26 (04) : 277 - 277
  • [40] Prostate-specific Membrane Antigen Based Antibody-drug Conjugates for Metastatic Castration-resistance Prostate Cancer
    Niaz, Muhammad O.
    Sun, Michael
    Ramirez-Fort, Marigdalia
    Niaz, Muhammad J.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (02)
12345